[PDF][PDF] VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal …
MA Dimopoulos, PG Richardson… - Journal of Clinical …, 2009 - researchgate.net
Journal of Clinical Oncology, 2009•researchgate.net
Purpose To assess bortezomib plus melphalan and prednisone (VMP) and melphalan and
prednisone (MP) in previously untreated patients with multiple myeloma (MM) with renal
impairment enrolled on the phase III VISTA study, and to evaluate renal impairment
reversibility.
prednisone (MP) in previously untreated patients with multiple myeloma (MM) with renal
impairment enrolled on the phase III VISTA study, and to evaluate renal impairment
reversibility.
Purpose
To assess bortezomib plus melphalan and prednisone (VMP) and melphalan and prednisone (MP) in previously untreated patients with multiple myeloma (MM) with renal impairment enrolled on the phase III VISTA study, and to evaluate renal impairment reversibility.
researchgate.net